Skip to content
Aerami Therapeutics

Aerami Therapeutics

Reimagining the treatment of chronic diseases with Inhaled Therapies

  • ABOUT US
  • Inhalation Technology
  • Pipeline
  • INVESTORS + MEDIA
  • CONTACT
  • linkedin
  • twitter

Dance Biopharm rebrands to Aerami Therapeutics

September 21, 2019
Continue Reading

Pharmaceutical company develops inhaled endocrine therapies

September 21, 2019
Continue Reading

Dance Biopharm Presents Phase 2 Clinical Data Highlighting Rapid Effects of Inhaled Human Insulin at European Association for the Study of Diabetes Meeting

September 19, 2019
Continue Reading

Dance Biopharm Partners With DarioHealth to Expand Access to Digital Therapeutics Platform for Patients With Chronic Diseases

September 11, 2019
Continue Reading

Dance Biopharm raises $21m for insulin delivery device

June 11, 2019
Continue Reading

Dance Biopharm to Present Data from Phase 2 Clinical Trial of Dance 501 Inhaled Insulin Therapy at American Diabetes Association Meeting

June 4, 2019
Continue Reading

10 diabetes drugs Bay Area biotech companies have in the pipeline

May 23, 2019
Continue Reading

Posts navigation

Newer posts

Categories

  • In The News
  • PRESS RELEASES

Archives

  • 2020
  • 2019
  • 2017

Investor Contact:

Steve Thornton
Aerami Therapeutics, Inc.
(919) 589-8862
sthornton@aerami.com

Media Contact:

Chad Whitaker
Aerami Therapeutics, Inc.
(919) 355-5864
cwhitaker@aerami.com

  • linkedin
  • twitter

2520 Meridian Parkway, Suite 400
Durham, North Carolina 27713
info@aerami.com

© 2020 Aerami Therapeutics.
All Rights Reserved.  Privacy Policy